Martin Brenoe
Stock Analyst at Nordea Markets
(0.60)
# 4,043
Out of 4,495 analysts
11
Total ratings
33.3%
Success rate
-16.4%
Average return
Main Sectors:
Stocks Rated by Martin Brenoe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0QIU Novo Nordisk A/S | Upgraded: Buy | kr 350.00 | $320.16 | +9.32% | 1 | Jun 19, 2026 | |
| ZLDPF Zealand Pharma A/S | Downgraded: Hold | n/a | $45.29 | - | 1 | Mar 6, 2026 | |
| NVO Novo Nordisk | Downgraded: Hold | n/a | $48.87 | - | 1 | Feb 24, 2026 | |
| WILLF Demant A/S | Upgraded: Buy | $51 → $35 | $40.23 | -12.76% | 3 | Feb 18, 2026 | |
| LON: 0NQC Pandora A/S | Upgraded: Buy | kr 300.00 → kr 1,200 | $780.60 | n/a | 3 | May 7, 2025 | |
| OSSFF Embla Medical hf. | Initiated Coverage: Buy | $5.77 | $4.15 | n/a | 1 | Jun 22, 2023 | |
| PNDRY Pandora A/S | Upgraded: Hold | n/a | $14.82 | n/a | 1 | Feb 9, 2023 |
Novo Nordisk A/S
Jun 19, 2026
Upgraded: Buy
Price Target: kr 350.00
Current: $320.16
Upside: +9.32%
Zealand Pharma A/S
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $45.29
Upside: -
Novo Nordisk
Feb 24, 2026
Downgraded: Hold
Price Target: n/a
Current: $48.87
Upside: -
Demant A/S
Feb 18, 2026
Upgraded: Buy
Price Target: $51 → $35
Current: $40.23
Upside: -12.76%
Pandora A/S
May 7, 2025
Upgraded: Buy
Price Target: kr 300.00 → kr 1,200
Current: $780.60
Upside: n/a
Embla Medical hf.
Jun 22, 2023
Initiated Coverage: Buy
Price Target: $5.77
Current: $4.15
Upside: n/a
Pandora A/S
Feb 9, 2023
Upgraded: Hold
Price Target: n/a
Current: $14.82
Upside: n/a